Compare NPO & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPO | DNTH |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 4.6B |
| IPO Year | 2002 | 2018 |
| Metric | NPO | DNTH |
|---|---|---|
| Price | $306.90 | $90.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $278.33 | $121.00 |
| AVG Volume (30 Days) | 203.0K | ★ 425.6K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $1,532,000,000.00 | $2,036,000.00 |
| Revenue This Year | $12.31 | N/A |
| Revenue Next Year | $6.39 | $29.48 |
| P/E Ratio | $243.54 | ★ N/A |
| Revenue Growth | ★ 16.98 | N/A |
| 52 Week Low | $178.22 | $16.77 |
| 52 Week High | $326.98 | $96.50 |
| Indicator | NPO | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 53.47 | 59.23 |
| Support Level | $294.00 | $81.16 |
| Resistance Level | $326.98 | $96.50 |
| Average True Range (ATR) | 10.08 | 4.45 |
| MACD | -1.27 | 0.25 |
| Stochastic Oscillator | 38.17 | 85.05 |
Enpro Inc formerly EnPro Industries Inc is a United States-based company that designs, develops, manufactures, and markets proprietary engineered industrial products. The company operates through two segments: Sealing Technologies, which derives maximum revenue, manufactures and markets sealing products, wheel-end components & systems; and Advanced Surface Technologies, which manufactures wafer processing sub-systems, thin-film coatings, optical filters, and other services like cleaning, coating, testing, and refurbishment. Its geographical segments are the United States, Europe, and other foreign countries.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.